The United States nebulizer market is set to grow from US$ 466.55 million in 2024 to US$ 730.62 million by 2033, with a CAGR of 5.11%. This growth is driven by the rising prevalence of respiratory ...

Ritedose receives FDA approval for Tobramycin Tobramycin expands nation's largest nebulized drug portfolio. - Generic Tobramycin Inhalation Solution marks the first cystic fibrosis (CF) product in the ...

An announcement from Liquidia Technologies ( ($LQDA) ) is now available. On October 27, 2025, Liquidia Technologies entered into an exclusive ...

A new review led by Associate Professor Sanjay Singhal from Dr. Ram Manohar Lohia Institute of Medical Sciences sheds light ...

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

Texas officials promised to help Rochelle care for her grandkids after taking them from their parents. But the help she ...

Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies October 28, 2025 2:00 ...

A new clinical practice guideline developed by a task force of the American Academy of Sleep Medicine provides updated ...

Nasacort takes up to a week to achieve full benefits for allergy symptoms, and should be used daily for optimal allergy ...

On the surface, a Medicare Advantage plan that charges no monthly premium seems like a better deal than original Medicare with a Medigap and Part D drug plan, which have monthly premiums but typically ...

Patients who depended on oral corticosteroids to care for their severe asthma experienced improvements in asthma control ...

This study update could positively impact Vertex Pharmaceuticals and Moderna’s stock performance, as successful results may enhance their competitive position in the cystic fibrosis treatment market.